A Registry Based Collaborative to Measure Efficiency, Effectiveness, and Safety of Farapulse PFA Technology for AF (DISRUPT-AF)
A Registry Based Collaborative to Measure Efficiency, Effectiveness, and Safety of Farapulse Pulsed Field Ablation Technology for Atrial Fibrillation
Sponsor: Boston Scientific Corporation
This observational or N/A phase trial investigates Atrial Fibrillation and is currently ongoing. Boston Scientific Corporation leads this study, which shows 10 recorded versions since 2024 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
10 versions recorded-
Nov 2025 — Present [monthly]
Enrolling By Invitation
-
Sep 2025 — Nov 2025 [monthly]
Enrolling By Invitation
-
Jul 2025 — Sep 2025 [monthly]
Enrolling By Invitation
-
May 2025 — Jul 2025 [monthly]
Enrolling By Invitation
-
Jan 2025 — May 2025 [monthly]
Enrolling By Invitation
▶ Show 5 earlier versions
-
Oct 2024 — Jan 2025 [monthly]
Enrolling By Invitation
Status: Not Yet Recruiting → Enrolling By Invitation
-
Sep 2024 — Oct 2024 [monthly]
Not Yet Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting
-
May 2024 — Jul 2024 [monthly]
Not Yet Recruiting
-
Apr 2024 — May 2024 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Boston Scientific Corporation
- Heart Rhythm Clinical and Research Solutions, LLC
For direct contact, visit the study record on ClinicalTrials.gov .